His special clinical interests include patients with type 1 diabetes, intensified insulin therapy, complicated type 2 diabetes patients, and hypoglycemia associated with diabetes. Dr Sherwin’s research activities span clinical and basic research and are focused on brain glucose sensing mechanisms mediating the activation of counterregulatory responses and the impact of hypoglycemia and insulin on brain function and metabolism as well as the changes in brain function that drive disordered glucose control and eating behavior using brain imaging techniques (fMRI, spectroscopy, and PET) in both diabetes and obesity. Dr. Sherwin has served as President of the American Diabetes Association and as a member of the FDA Advisory Committee for Endocrinologic and Metabolic Drugs. He has served as the Chairman of the Medical Science Advisory Board of the JDRF and on the editorial boards of leading diabetes and endocrine journals. He has published over 400 articles in peer-reviewed journals and is the recipient of numerous scientific awards including the American Diabetes Association’s Banting Award for lifetime scientific achievement, the Novartis Award for long-standing achievement in diabetes, and 2 MERIT Awards from the NIH.